PARLIAMENTARY WRITTEN QUESTION
Pancreatic Cancer: Medical Treatments (4 January 2016)
Question Asked
To ask the Secretary of State for Health, when his Department plans to make a decision on whether to refer for consideration by NICE PRRNT treatment for pancreatic cancers.
Asked by:
Karin Smyth (Labour)
Asked by:
Karin Smyth (Labour)
Answer
The National Institute for Health and Care Excellence (NICE) has recently consulted stakeholders on the suitability of Lutetium-177 Dotatate - a type of peptide receptor radionuclide therapy (PRRT) - for treating unresectable, somatostatin receptor-positive gastroentero-pancreatic neuroendocrine tumours without disease progression for referral to its technology appraisal work programme. A decision on its referral to NICE will be taken shortly.
Answered by:
George Freeman (Conservative)
7 January 2016
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.